Get notified when PURR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Going Concern (unchanged) — Sonnet BioTherapeutics disclosed substantial doubt about ability to continue as going concern due to recurring losses, negative cash flows since inception, and cash of $5.1M at September 30, 2025 expected to fund operations only into February 2026.
- Cryptocurrency Treasury Strategy (unchanged) — Filing discloses a named Bitcoin treasury/financing strategy (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material.
Hyperliquid Strategies raises $647M net via equity facility; Sonnet merger closed Dec 2025
Filed July 21, 2026 · Compared to S-1/A Jun 25, 2026 · ~1 min read
Key Changes
-
high
As discussed in Note 1, on Decemb…
Notes: Subsequent Events verify on EDGAR → -
high
Company issued ~76.1M shares through July 15, 2026, generating $647M net proceeds primarily used to purchase HYPE tokens via committed equity facility with Chardan Capital Markets.
MD&A: Equity Facility verify on EDGAR → -
high
Business combination with Rorschach and Sonnet BioTherapeutics closed December 2, 2025; combined entity began trading under ticker PURR on December 3, 2025. Sonnet operates as wholly owned subsidiary focused on biotech asset SON-1010.
Business: Merger Completion view on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (INBP 10-K) is open in full — no account needed.
Partner
Trade PURR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 22, 2026 · How we verify